Hybrid Collagenase Nanocapsules for Enhanced Nanocarrier Penetration in Tumoral Tissues
Source abstract
Abstract
Poor penetration of drug delivery nanocarriers within dense extracellular matrices constitutes one of the main liabilities of current nanomedicines. The conjugation of proteolytic enzymes on the nanoparticle surface constitutes an attractive alternative. However, the scarce resistance of these enzymes against the action of proteases or other aggressive agents present in the bloodstream strongly limits their application. Herein, a novel nanodevice able to transport proteolytic enzymes coated with an engineered pH-responsive polymeric is presented. This degradable coat protects the housed enzymes against proteolytic attack at the same time that it triggers their release under mild acidic conditions, usually present in many tumoral tissues. These enzyme nanocapsules have been attached on the surface of mesoporous silica nanoparticles, as nanocarrier model, showing a significatively higher penetration of the nanoparticles within 3D collagen matrices which housed human osteosarcoma cells (HOS). This strategy can improve the therapeutic efficacy of the current nanomedicines, allowing a more homogeneous and deeper distribution of the therapeutic nanosystems in cancerous tissues.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Protease and Inhibitor Mechanisms · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Departamento Química Inorgánica y Bioinorgánica, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, Plaza Ramón y Cajal s/n, Madrid 28040, Spain
Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Avenida Monforte de Lemos, 3-5, Madrid 28029, Spain
Funding
Ministerio de Economía y Competitividad
References (26)
Show source-provided references
1. 10.1021/ab500084g10.1021/ab500084g ↗
2. 10.1016/j.addr.2012.10.00210.1016/j.addr.2012.10.002 ↗
3. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
4. 10.1016/j.jconrel.2012.03.02210.1016/j.jconrel.2012.03.022 ↗
5. Netti P. · Cancer Res. · 2000 · 60 · 2497
6. 10.1016/j.jconrel.2011.09.06310.1016/j.jconrel.2011.09.063 ↗
7. 10.1021/nn202163v10.1021/nn202163v ↗
8. 10.1002/anie.20120190210.1002/anie.201201902 ↗
9. 10.1158/0008-5472.CAN-05-224210.1158/0008-5472.CAN-05-2242 ↗
10. 10.1021/nl052241g10.1021/nl052241g ↗
11. 10.1021/nn502807n10.1021/nn502807n ↗
12. 10.1016/j.enzmictec.2007.01.01810.1016/j.enzmictec.2007.01.018 ↗
13. 10.1038/nnano.2009.34110.1038/nnano.2009.341 ↗
14. 10.1038/nnano.2012.26410.1038/nnano.2012.264 ↗
15. 10.1002/adfm.20140072910.1002/adfm.201400729 ↗
16. 10.1039/C4NR02459A10.1039/C4NR02459A ↗
17. 10.1016/j.jconrel.2010.08.02710.1016/j.jconrel.2010.08.027 ↗
18. 10.1517/17425247.2014.95305110.1517/17425247.2014.953051 ↗
19. 10.1021/cm001155910.1021/cm0011559 ↗
20. 10.1002/anie.20050307510.1002/anie.200503075 ↗
21. 10.1016/j.addr.2012.07.01810.1016/j.addr.2012.07.018 ↗
22. 10.1016/0167-4838(95)00133-F10.1016/0167-4838(95)00133-F ↗
23. 10.1016/j.jconrel.2014.12.01810.1016/j.jconrel.2014.12.018 ↗
24. Goodman T. T. · Int. J. Nanomedicine · 2007 · 2 · 26510.2217/17435889.2.3.265 ↗
25. 10.1002/adma.20110476310.1002/adma.201104763 ↗
26. 10.1021/nn800072t10.1021/nn800072t ↗